
    
      Conditioning therapy

        -  Cytoxan 50 mg/kg/d on d-3 to -2

        -  Fludarabine 30 mg/m2 on d-6 to -2

        -  Antithymocyte globulin (ATG; ThymoglobulinÂ®) 1.5 mg/kg/d (for HLA-matched sibling donor
           HCT) or 3.0 mg/kg/d (for other alternative donor HCT)

        -  Methylpd 2 mg/kg/d on d-4 to -1

      Mobilization and harvest

        -  G-CSF 10 mcg/kg/d s.c. on d-3 to 0

        -  Harvest of PBMCs on d 0 to +1

      Donor G PBMC infusion

        -  Infuse G-PBMCs on d 0 to d+1.

      GVHD prophylaxis

        -  Cyclosporine 1.5 mg/kg i.v. q 12 hrs beginning on d-1 and changed to oral dosing (with
           twice the i.v. dose) when oral intake is possible. Tapered beginning between d+30 and
           d+60.

        -  Methotrexate 15 mg/m2 i.v. on d+2, and 10 mg/m2 i.v. on d+4 and d+7

      Preemptive dose-escalating DLIs

        -  Begin at d+120 or at least 2 wks after IST discontinuation.

        -  Failure to achieve full donor chimerism No evidence of GVHD

        -  CD3+ cell dose increment q 4 wks -+ cell dose: HLA-matched donor HCT (1 x 107/kg, 5 x
           107/kg, 1 x 108/kg), HLA-matched unrelated donor HCT (1 x 106/kg, 5 x 106/kg, 1 x
           107/kg), HLA-matched familial donor HCT (1 x 105/kg, 5 x 105/kg, 1 x 106/kg)
    
  